Dr Jo Elizabeth Hegarty

MB Bch BAO, MRCPCH (UK), PG Dip AeroRT (Otago)

Research | Current

hPOD

hypoglycaemia Prevention with Oral Dextrose in newborn babies

Hypoglycaemia is the commonest metabolic disorder of the newborn, and the only known common preventable cause of brain damage in newborn babies.  Neonatal hypoglycaemia treatment commonly requires admission to the newborn intensive care unit (NICU), separating mothers and babies and interfering with the establishment of breast-feeding, thus incurring high social and financial cost.

hPOD is a multi-centre, double-blinded, randomised, placebo-controlled trial, comparing 40% dextrose gel with an identically appearing placebo gel.  Babies who are at risk of hypoglycaemia (infants of diabetic mothers, preterm, small- or large-for-gestational age, other e.g. maternal medication) and unlikely to require NICU admission for other reasons are randomised to receive 40% dextrose gel or identically appearing placebo gel.  The primary outcome is admission to NICU; secondary outcomes include incidence of hypoglycaemia, breastfeeding rates, costs of care before discharge and assessment of neurodevelopmental outcome at 2 years of age.

For more information see: http://www.liggins.auckland.ac.nz/uoa/hpod-study

Areas of expertise

Neonatology

Selected publications and creative works (Research Outputs)

Identifiers

Contact details

Primary location

AUCKLAND HOSPITAL - Bldg 599
Level 3, Room 33.013
2 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links